Role of the inflammatory activity in haemodialysis patients with COVID-19 Inflammatory activity, COVID-19
Main Article Content
Objectives: It is known that haemodialysis (HD) patients are older and have more co-morbidities, and therefore they are very susceptible against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Inflammatory activity plays an important role in coronavirus disease 2019 (COVID-19), and the intensity of inflammatory response makes the severity of COVID-19 worse. Biomarkers related to infection such as procalcitonin (PCT), C-reactive protein (CRP), ferritin, albumin, troponin I, D-dimer, white blood cell (WBC), neutrophil, lymphocyte, and platelet play an important role in the inflammatory response of COVID-19. Our objective is to compare these biomarkers between healthy individuals with COVID-19 (HI-COVID-19) and haemodialysis (HD) patients (HP-COVID-19).
Methods: 50 patients diagnosed with COVID-19 were included in this cross-sectional and monocentric retrospective study. The population of this study was separated into two groups: Group 1 consisted of HI-COVID-19 (n=27), and Group 2 consisted of HP-COVID-19 (n=23). Demographic data, basic clinical characteristics, and laboratory tests were recorded during the application. Group 2 participants were chosen from those whose biomarkers such as ferritin (<200 ng/mL), CRP, PCT, ferritin, albumin, D-dimer, troponin I, WBC, neutrophil, lymphocyte, and platelet were within the normal range three months before (prior to having COVID-19).
Findings: When Group 2 and Group 1 were compared in terms of gender, age, presence of lung uptake, and fever, there was no difference. Five HP-COVID-19 patients lost their lives. There were no deaths in the other group. There was a statistically significant difference. Comorbid diseases such as diabetes mellitus (DM), coronary artery disease (CAD), and hypertension (HT) were significantly higher in Group 2. It was observed that CRP, PCT, troponin I, D-dimer, and ferritin from biochemical parameters were higher in Group 2, and platelet and albumin were higher in Group 1. Although WBC and neutrophil elevations and low lymphocytes were detected in Group 2, it was statistically not significant. Tocilizumab and convalescent plasma use were significantly higher in Group 2.
Conclusions: The strength of inflammatory activity in HP-COVID-19 can be estimated by observing serum levels of biomarkers such as CRP, PCT, ferritin, albumin, D-dimer, troponin I, WBC, neutrophil, lymphocyte, and platelet.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 Novel Coronavirus (2019-nCoV) infections among travelers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5):2000062. Doi: 10.2807/1560-7917.ES.2020.25.5.2000062.
Hui DS, Azhar EI, Madani TA. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266. Doi: 10.1016/j.ijid.2020.01.009.
US Renal Data System. https://www.usrds.org/Default.aspx Accessed March 3, 2020.
Chinese National Renal Data System. http://www.cnrds.net/Static/OfficialDocumentDown.html. Accessed 2020
Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. Doi: 10.1016/j.clim.2020.108393
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280. Doi: 10.1016/j.cell.2020.02.052
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. Doi: 10.1038/s41577-020-0311-8
Siu KL, Yuen KS, Castaño-Rodriguez C, et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. 2019;33(8):8865–77. Doi: 10.1096/fj.201802418R.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-513. Doi: 10.1016/S0140-6736(20)30211-7.
Xiong F, Tang H, Liu L, et al. Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. JASN. 2020;31 (7):1387-1397; Doi:10.1681/ASN.2020030354
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382(18):1708–1720. Doi: 10.1056/NEJMoa2002032.
Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) medRxiv. 2020. Doi: 10.1101/2020.02.10.20021832.
National Health and Health Commission of the People’s Republic of China. Diagnosis and Treatment of Pneumonia of New Coronavirus Infection 2020, http://www.nhc.gov.cn/jkj/s3578/202002/dc7f3a7326e249c0bad0155960094b0b.shtml.
Newberry WM, Sanford JP. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest. 1971;50(6):1262–1271. Doi: 10.1172/JCI106604.
Soriano S, Martín-Malo A, Carracedo J, Ramírez R, Rodríguez M, Aljama P. Lymphocyte apoptosis: role of uremia and permeability of dialysis membrane. Nephron Clin Pract. 2005;100(3):71–77. Doi: 10.1159/000085051.
Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20(5):440-51. Doi: 10.1111/j.1525-139X.2007.00283. x.
Borges A, Borges M, Fernandes J. Apoptosis of peripheral CD4(+) T-lymphocytes in end-stage renal disease patients under hemodialysis and rhEPO therapies. Ren Fail. 2011;33(2):138–143. Doi: 10.3109/0886022X.2011.553300.
Freitas GRR, da Luz Fernandes M, Agena F. Aging and end stage renal disease cause a decrease in absolute circulating lymphocyte counts with a shift to a memory profile and diverge in Treg population. Aging Dis. 2019;10(1):49–61. Doi: 10.14336/AD.2018.0318.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5
Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidity. J Med Virol. 2020;92(10):2152-2158. Doi: 10.1002/jmv.26003.
Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. Doi: 10.1016/j.jcv.2020.104370.
Mehta P, McAuley DF, Brown M, et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033‐1034. Doi:10.1016/S0140-6736(20)30628-0
Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail. 2020;26(6):470–475. Doi: 10.1016/j.cardfail.2020.04.009.
Yu B, Li X, Chen J, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis. 2020:1–10. Doi: 10.1007/s11239-020-02171-y
Zaid Y, Puhm F, Allaeys I, et al. Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19. Circ Res. 2020;127(11):1404–1418. Doi: 10.1161/CIRCRESAHA.120.317703